Iovance Biotherapeutics

Iovance Biotherapeutics, Inc.
FormerlyLion Biotechnologies, Inc.
TypePublic
Industry
Founded2007 (2007)
HeadquartersSan Carlos, California, U.S.
Key people
Steven Rosenberg Interim CEO: Frederick G. Vogt[1]
Number of employees
319 (December 31, 2021)
Websiteiovance.com

Iovance Biotherapeutics, Inc. is a biopharmaceutical company based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.[2][3]

History

The company was founded in 2007 as Genesis Biopharma. In 2013, Lion merged with Genesis Biopharma аnd became Lion Bio Pharma,[4] which was then rebranded to Iovance in 2017.[5]

In 2024, the US FDA gave accelerated approval to Lifileucel, marketed under the brand name Amtagvi, the company's tumor-infiltrating lymphocyte drug for the treatment of unresectable or metastatic melanoma.[6][7]

TIL monotherapy and TIL combination therapies are being investigated by Iovance in multiple clinical studies in multiple advanced solid tumor cancers such as NSCLC and sarcoma.[8]

See also

References

  1. ↑ https://www.iovance.com/management/
  2. ↑ Garber, Ken (7 August 2019). "Pursuit of tumor-infiltrating lymphocyte immunotherapy speeds up". Nature Biotechnology. Retrieved 14 August 2019.
  3. ↑ Adelman, Jacob (29 May 2019). "New Navy Yard lab and office complex planned for Calif. cell-therapy research firm Iovance". The Philadelphia Inquirer. Retrieved 14 August 2019.
  4. ↑ "Genesis Biopharma completes merger with Lion Biotech". www.thepharmaletter.com. Retrieved 2026-03-10.
  5. ↑ "Genesis Biopharma Announces Completion of Merger with Lion Biotechnologies". www.businesswire.com. 2013-07-25. Retrieved 2020-01-17.
  6. ↑ "Amtagvi US FDA". FDA. 31 July 2024.
  7. ↑ Mullard, Asher (2024-02-19). "FDA approves first tumour-infiltrating lymphocyte (TIL) therapy, bolstering hopes for cell therapies in solid cancers". Nature Reviews Drug Discovery. doi:10.1038/d41573-024-00035-1. PMID 38374249.
  8. ↑ https://ir.iovance.com/static-files/b9ec0908-66bb-47d6-8e51-9b55031194c1
  • Official website
  • Business data for Iovance Biotherapeutics, Inc.:
This page is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.